These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38577865)

  • 21. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(ortho ester) nanoparticles targeted for chronic intraocular diseases: ocular safety and localization after intravitreal injection.
    Li H; Palamoor M; Jablonski MM
    Nanotoxicology; 2016 Oct; 10(8):1152-9. PubMed ID: 27108911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biodegradable implants for sustained drug release in the eye.
    Lee SS; Hughes P; Ross AD; Robinson MR
    Pharm Res; 2010 Oct; 27(10):2043-53. PubMed ID: 20535532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular drug delivery system: a reference to natural polymers.
    Pahuja P; Arora S; Pawar P
    Expert Opin Drug Deliv; 2012 Jul; 9(7):837-61. PubMed ID: 22703523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.
    Vaneev A; Tikhomirova V; Chesnokova N; Popova E; Beznos O; Kost O; Klyachko N
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles for drug delivery to the anterior segment of the eye.
    Janagam DR; Wu L; Lowe TL
    Adv Drug Deliv Rev; 2017 Dec; 122():31-64. PubMed ID: 28392306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease.
    Faria MJ; González-Méijome JM; Real Oliveira MECD; Carracedo G; Lúcio M
    Adv Drug Deliv Rev; 2024 Jul; 210():115321. PubMed ID: 38679293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of Nanotechnology-mediated Herbal Nanosystems for Ophthalmic Drug.
    Shree D; Patra CN; Sahoo BM
    Pharm Nanotechnol; 2024; 12(3):229-250. PubMed ID: 37587812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimuli-Responsive Polymeric Systems for Controlled Protein and Peptide Delivery: Future Implications for Ocular Delivery.
    Mahlumba P; Choonara YE; Kumar P; du Toit LC; Pillay V
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Review on the Role of Polymers in Ocular Drug Delivery.
    Paramjot ; Wadhwa S; Sharma A; Singh SK; Vishwas S; Kumar R; Singh S; Dua K; Chellappan DK; Gupta G
    Curr Drug Deliv; 2024; 21(1):16-37. PubMed ID: 36627785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
    Gote V; Ansong M; Pal D
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of biopolymers as carriers of antiphlogistic agents for treatment of diverse ocular inflammations.
    Sharma AK; Arya A; Sahoo PK; Majumdar DK
    Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():779-791. PubMed ID: 27287177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
    Del Amo EM; Urtti A
    Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles.
    Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
    Eur J Pharm Biopharm; 2017 Jan; 110():58-69. PubMed ID: 27789359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
    Wu Y; Li X; Fu X; Huang X; Zhang S; Zhao N; Ma X; Saiding Q; Yang M; Tao W; Zhou X; Huang J
    Adv Sci (Weinh); 2024 Aug; 11(32):e2403399. PubMed ID: 39031809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
    Lakhani P; Patil A; Majumdar S
    Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ISOPT
    Kompella UB; Domb A; Urtti A; Jayagopal A; Wilson CG; Tang-Liu D
    J Ocul Pharmacol Ther; 2019 Oct; 35(8):457-465. PubMed ID: 31259643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders.
    Mandal S; Vishvakarma P; Bhumika K
    Curr Drug Res Rev; 2024; 16(3):251-267. PubMed ID: 38158868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.